Noninvasive Prenatal Test Launched
|
By LabMedica International staff writers Posted on 21 May 2012 |
|
An innovative noninvasive test detects common fetal trisomies utilizing a directed approach to analyze cell-free DNA (cfDNA) in maternal blood.
The test is performed using a simple maternal blood draw taken at a doctor's office or patient service center, and provides the safety of screening tests with accuracy approaching that of invasive testing for common fetal trisomies.
The Harmony Prenatal Test, which detects common fetal trisomies such as Trisomy 21 which is associated with Down syndrome, will be offered through Laboratory Corporation of America Holdings (LabCorp, Burlington, NC, USA) and will be available at its more than 1,000 patient service centers. The test is available to pregnant women of at least 10 weeks gestational age with a single fetus conceived without the use of an egg donor.
The Harmony Prenatal Test will be available in the United States and Canada through Integrated Genetics, a member of LabCorp's Specialty Testing Group. The test is a product of the molecular diagnostics company Ariosa Diagnostics (San Jose, CA, USA). Compared to random sequencing, directed cfDNA analysis is simpler, less costly, and more precise. It also provides individualized prenatal test results for trisomy risk.
Ken Song, MD, chief executive officer at Ariosa Diagnostics, said, "Ariosa Diagnostics is very excited to announce the official launch of the Harmony Prenatal Test and the agreement with LabCorp, which helps us deliver on the promise of bringing an affordable and accessible prenatal testing option to pregnant women and their physicians. With enhanced test performance and simplicity, the Harmony Prenatal Test can be reliably incorporated into the management of pregnancies."
Mark Brecher, MD, LabCorp's chief medical officer, added, "We are pleased to be able to offer this novel, noninvasive prenatal test. Ariosa Diagnostics' Harmony Prenatal Test adds another option to LabCorp's comprehensive prenatal testing menu." Integrated Genetics is a business unit of Esoterix Genetic Laboratories (Austin, TX, USA), a wholly-owned subsidiary of Laboratory Corporation of America Holdings.
Related Links:
Laboratory Corporation of America Holdings
Ariosa Diagnostics
Esoterix Genetic Laboratories
The test is performed using a simple maternal blood draw taken at a doctor's office or patient service center, and provides the safety of screening tests with accuracy approaching that of invasive testing for common fetal trisomies.
The Harmony Prenatal Test, which detects common fetal trisomies such as Trisomy 21 which is associated with Down syndrome, will be offered through Laboratory Corporation of America Holdings (LabCorp, Burlington, NC, USA) and will be available at its more than 1,000 patient service centers. The test is available to pregnant women of at least 10 weeks gestational age with a single fetus conceived without the use of an egg donor.
The Harmony Prenatal Test will be available in the United States and Canada through Integrated Genetics, a member of LabCorp's Specialty Testing Group. The test is a product of the molecular diagnostics company Ariosa Diagnostics (San Jose, CA, USA). Compared to random sequencing, directed cfDNA analysis is simpler, less costly, and more precise. It also provides individualized prenatal test results for trisomy risk.
Ken Song, MD, chief executive officer at Ariosa Diagnostics, said, "Ariosa Diagnostics is very excited to announce the official launch of the Harmony Prenatal Test and the agreement with LabCorp, which helps us deliver on the promise of bringing an affordable and accessible prenatal testing option to pregnant women and their physicians. With enhanced test performance and simplicity, the Harmony Prenatal Test can be reliably incorporated into the management of pregnancies."
Mark Brecher, MD, LabCorp's chief medical officer, added, "We are pleased to be able to offer this novel, noninvasive prenatal test. Ariosa Diagnostics' Harmony Prenatal Test adds another option to LabCorp's comprehensive prenatal testing menu." Integrated Genetics is a business unit of Esoterix Genetic Laboratories (Austin, TX, USA), a wholly-owned subsidiary of Laboratory Corporation of America Holdings.
Related Links:
Laboratory Corporation of America Holdings
Ariosa Diagnostics
Esoterix Genetic Laboratories
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Repetitive Pipette
VWR® Stepper Pro
Hematology Consumables
Bioblood Devices
Latest Molecular Diagnostics News
- Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
- New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
- Blood-Based RNA Test May Predict Chemotherapy Sensitivity in Lung Cancer
- Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
- Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
- Researchers Uncover Distinct Chromosome Signature in Aggresive ALT Cancers
- Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
- Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
- Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer
- Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
- Multi-Cancer Test Boosts Detection When Added to Standard Screening
- Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia
- Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer
- Blood Protein Markers Flag Multiple Sclerosis Risk Years Before Diagnosis
- Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
- Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
Channels
Clinical Chemistry
view channel
Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read more
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read more
Immunology
view channel
Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Microbiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read more
Pathology
view channel
AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
Meningiomas are the most common primary brain tumors in adults, yet their course ranges from indolent to highly recurrent disease. Estimating an individual patient’s recurrence risk often requires advanced... Read more
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Technology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read more
Industry
view channel
Genetic Testing Program Expands Detection of Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency (AATD) is a progressive genetic condition, the leading known genetic risk factor for chronic obstructive pulmonary disease (COPD), and a cause of liver disease in both children... Read more
